1-8 of 8
Svea K. Wahlstrom
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Krish Patel, Anna Teschemaker, Hongping Tian, Nick Pyrih, Geert Kolvenbag, Shweta Patel, Svea K. Wahlstrom, Lianzhou Cui
Journal: Blood
Blood (2024) 144 (Supplement 1): 7744.
https://doi.org/10.1182/blood-2024-194523
Published: 2024
Journal Articles

Real-World Risk of Major Bleeding Events in BTKi-Treated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Javid J. Moslehi, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Brittaney-Belle Elizabeth Gordon, Ning A. Rosenthal
Journal: Blood
Blood (2024) 144 (Supplement 1): 5109.
https://doi.org/10.1182/blood-2024-198681
Published: 2024
Journal Articles

Real-World Bleeding Risk, Outcomes and Treatment Patterns of Patients with CLL/SLL Receiving BTKi with or without Prescription Anticoagulants or Antiplatelets

Brittaney-Belle Elizabeth Gordon, Svea K. Wahlstrom, Anna Teschemaker, Rachel H. Mackey, Diana DeVincenzo, Leslie A. Carabuena, Samantha L. Thompson, Ning A. Rosenthal, Javid J. Moslehi
Journal: Blood
Blood (2024) 144 (Supplement 1): 5105.
https://doi.org/10.1182/blood-2024-198724
Published: 2024
Journal Articles

Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma

Ryan W Jacobs, Anna Teschemaker, Shweta Hakre, Hongping Tian, Nick Pyrih, Svea K. Wahlstrom, Lianzhou Cui
Journal: Blood
Blood (2023) 142 (Supplement 1): 5151.
https://doi.org/10.1182/blood-2023-174974
Published: 2023
Journal Articles

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Lindsey E. Roeker, Maral DerSarkissian, Kellie J. Ryan, Yan Chen, Svea K. Wahlstrom, Shweta Hakre, Louise Yu, Helen Guo, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 4156–4158.
https://doi.org/10.1182/blood-2022-167213
Published: 2022
Journal Articles

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, Svea K. Wahlstrom, Maral DerSarkissian, Colin Kunzweiler, Felicia Castriota, Rose Chang, Hoi Ching Cheung, Yuqian Gu, Helen Guo, Mei Sheng Duh, Kellie J. Ryan
Journal: Blood
Blood (2021) 138 (Supplement 1): 2999.
https://doi.org/10.1182/blood-2021-147449
Published: 2021
Journal Articles

How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

Kellie Ryan, MPH, Hannah Le, PharmD, MPH, Svea K. Wahlstrom, VMD, MS, Kathleen Beusterien, MPH, Oliver Will, PhD, Martine C. Maculaitis, PhD, Thomas W. Leblanc
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-138952
Published: 2020
Journal Articles

Understanding Clinician and Patient Preferences about Novel Agents in Chronic Lymphocytic Leukemia

Hannah Le, PharmD, MPH, Trudy Pendergraft, MSPH, Svea K. Wahlstrom, VMD, MS, Kellie Ryan, MPH, Laura Sarokin, PhD, Emily Mulvihill, MBA, Thomas Campbell, PhD, Martine C. Maculaitis, PhD, Thomas W. LeBlanc, MDMA,MHS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4730.
https://doi.org/10.1182/blood-2019-129606
Published: 2019